BranchLab Secures $26 Million Series A Financing to Transform Pharma Commercialization with AI Platform

BranchLab has secured a $26 million Series A financing led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The company is partnering with leading pharmaceutical companies to replace fragmented, offline workflows with a unified, privacy-first AI platform. This platform is driving a nearly 70% increase in commercialization efficacy. Pharma commercialization, including patient identification, audience segmentation, activation, and real-world measurement, has historically relied on fragmented vendors, delayed analytics, and manual workflows.

However, BranchLab is changing the landscape by providing a unified AI platform that enables pharma teams to act on high-intent patient and healthcare professional audiences in near real time. The company has already delivered an average increase of nearly 70% in marketing efficacy across various therapeutic areas. BranchLab's CEO, Josh Walsh, emphasized the challenge of using rich data quickly and responsibly in the pharmaceutical industry, which the company aims to solve by turning privacy-safe, aggregated data into real-time insights that link directly to activation.

The platform's transformer-based architecture allows models to train on health data within customer-controlled environments, while deploying only non-sensitive demographic and media-side signals. With the new funding, BranchLab plans to expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and continue building the unified AI platform for pharma commercialization.